Liraglutide vs semaglutide: daily vs weekly
Liraglutide (Saxenda for weight loss, Victoza for diabetes) is the daily GLP-1 that preceded once-weekly semaglutide. Its much shorter half-life (~13 hours vs ~165 for semaglutide) creates very different dose patterns, very different side-effect curves, and different practical use cases.
The half-life difference
| Property | Liraglutide | Semaglutide |
|---|---|---|
| Half-life | ~13 hours | ~165 hours |
| Dosing | Daily subq | Once weekly subq |
| Steady-state reached | ~3 days | ~4–5 weeks |
| Doses per year | 365 | 52 |
| Plasma curve | Smooth, near-constant | Peak-trough pattern |
Why the half-life is so different
Both drugs are acylated GLP-1 analogs — modifications of the natural GLP-1 sequence designed to bind albumin in plasma, slowing renal clearance. Semaglutide's acyl modification (a longer fatty-acid chain through a γ-Glu spacer) produces much stronger albumin binding than liraglutide's. Result: semaglutide circulates bound to albumin for days, while liraglutide cycles through faster.
Efficacy comparison
| Drug / Dose / Trial | Weight loss at ~1 year |
|---|---|
| Liraglutide 3.0 mg (Saxenda, SCALE) | ~5.4–8.0% |
| Semaglutide 2.4 mg (Wegovy, STEP-1) | ~14.9% |
| Tirzepatide 15 mg (SURMOUNT-1) | ~20.9% |
Semaglutide produces roughly double liraglutide's weight loss. The difference traces to both higher labeled doses (semaglutide 2.4 mg vs liraglutide 3.0 mg — but on a molar basis the semaglutide dose is much larger) and stronger receptor binding.
When daily dosing is the right call
- Very-early-titration tolerance check. A daily drug can be stopped immediately if tolerability is poor. A weekly drug "stops" only by waiting out 4–5 weeks of plasma decay. For patients particularly anxious about GLP-1 effects, the daily option provides a faster off-ramp.
- Day-to-day flexibility. Some patients with shift work, irregular schedules, or specific clinical situations prefer the option to skip a dose without losing 1/7 of weekly exposure.
- Specific clinical indications. Liraglutide is approved for pediatric obesity (Saxenda, ages 12+) where semaglutide isn't yet. It's also the first-line GLP-1 in some health-system formularies.
- Cost / access reasons. Liraglutide goes off patent earlier; generic formulations may be available. Saxenda and Victoza have different insurance coverage than Ozempic and Wegovy in many plans.
When weekly dosing wins
- Adherence. 52 injections per year is more sustainable than 365 for most users. Long-term real-world adherence is much higher for weekly drugs.
- Side-effect tolerability. Weekly peaks are tolerated better than daily dose perturbations for many patients (counterintuitive but observed).
- Efficacy. Particularly at the higher doses, weekly drugs win on weight loss and glycemia.
- Travel. Fewer injections, less frequent pen storage logistics, less risk of missed doses while away from routine.
Side-effect profile
The two drugs have similar GI side-effect spectra (nausea, vomiting, diarrhea, constipation). The pattern differs:
- Liraglutide: daily mild nausea that fades over weeks. No "injection day worst" pattern.
- Semaglutide: 48–72 hour peak nausea each week, then quieter days 5–7.
Some patients tolerate one pattern much better than the other for personal reasons. There's no theoretical predictor — trial and error.
Switching between them
Switching liraglutide → semaglutide requires re-titration: stop liraglutide for ~3 days (let plasma drop), then start semaglutide at 0.25 mg. The receptors are adapted but the plasma profile is so different that effective re-titration is required.
Switching semaglutide → liraglutide: wait ~4 weeks after the last semaglutide dose (plasma decay to baseline), then start liraglutide at 0.6 mg. Faster transition than the other direction but still requires the off-window.
Liraglutide's current role
In 2026, liraglutide is mostly a second-line GLP-1 in countries where semaglutide and tirzepatide are available. Its role is:
- Pediatric obesity (Saxenda is currently the only GLP-1 with this label down to age 12).
- Patients who specifically need or prefer daily dosing.
- Cost-constrained access where generic liraglutide is available.
- Patients who didn't tolerate semaglutide or tirzepatide despite reasonable titration attempts.
FAQ
Can I take liraglutide every other day instead of daily?
No. The half-life is too short — every-other-day dosing creates large peak-trough swings that worsen tolerance. Daily is the labeled and clinically used cadence.
Why didn't liraglutide produce the obesity revolution semaglutide did?
Weaker efficacy and daily-injection adherence. Saxenda was available for years before Wegovy and never reached comparable uptake despite similar mechanism.
Is liraglutide cheaper than semaglutide?
Branded products are similarly priced. Generic liraglutide is starting to appear in some markets and may produce a cost advantage. Check local pricing; the gap is small but real.
Does liraglutide cause less muscle loss than semaglutide?
No reliable evidence of a difference once you control for total weight loss. The fat:lean ratio appears similar across the drugs at equivalent weight-loss magnitudes.
Related reading
Manage daily or weekly schedules
Peptide Protocol handles any dosing cadence — daily, weekly, or per-dose-specific — in one consistent schedule view.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.